Sodium-glucose cotransporter-2 (SGLT2) inhibitors were originally introduced as a novel class of antidiabetic drugs, while several recent clinical trials have shown that they have heart and kidney protective effects in chronic kidney disease (CKD) patients both with and without diabetes [8,9,10]. The gene discussed is SLC5A2; the disease is diabetes mellitus.